CVS Health shares get boost after Truist lifts price target to $108

CVS Health’s stock drew renewed Wall Street attention after Truist Financial lifted its price target for the company to $108 from $102 and maintained a “Buy” rating on June 1, according to market coverage of the analyst note. The adjustment arrives as CVS has been working through a margin recovery effort inside its health insurance business and as it has updated full-year 2026 financial guidance following recent results.

The catalyst for the shift in expectations appears tied to CVS’s latest earnings update. In its first-quarter 2026 release, CVS reported total revenues of $100.4 billion, up 6.2% year over year. The company posted GAAP diluted earnings per share of $2.30 and adjusted EPS of $2.57, with management attributing the adjusted figure primarily to improved adjusted operating income in the Health Care Benefits segment and execution on its margin recovery plan.

CVS also increased its 2026 outlook. The company raised its full-year GAAP diluted EPS guidance range to $6.24 to $6.44 (from $5.94 to $6.14), lifted adjusted EPS guidance to $7.30 to $7.50 (from $7.00 to $7.20), and increased its cash flow from operations guidance to at least $9.5 billion (from at least $9.0 billion). CVS said it was taking these steps to reflect expected improvements in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining caution for the remainder of the year amid elevated cost trends and potential macro headwinds.

Beyond the headline earnings numbers, CVS used the quarter to highlight operational changes in Aetna, its insurance business. The company said a Medicare Advantage final rate notice and home health assessment policy from the Centers for Medicare & Medicaid Services provided more performance clarity for 2027. CVS also described progress in streamlining prior authorization processes, including that it standardized data requirements for 88% of prior authorization volume, approved more than 95% of eligible prior authorizations within 24 hours, and processed 83% of prior authorizations in real time.

In technology and care delivery, CVS disclosed that it has launched Health100, a health technology services subsidiary intended to build a “fully integrated” health care engagement platform. CVS said Health100 will use Google Cloud’s AI technologies to support a connected, proactive, and personalized experience for consumers, reflecting the company’s effort to couple benefits administration and pharmacy services with more data-driven engagement.

Truist’s decision to raise the target and keep a Buy rating, as described in third-party coverage, suggests the note’s authors believed CVS’s momentum was durable enough to support a higher expected valuation range. In public summaries of the analyst move, market outlets linked the change to CVS’s reported earnings and guidance, including an implication of upside versus the prior close.

Still, some details are not fully verifiable from public reporting. The full Truist research note itself is not included in the coverage, so the specific model inputs, assumptions, and risk framework driving the $108 target were not disclosed. Separately, while CVS’s guidance updates are public, analysts can differ on how much of a margin recovery is sustainable versus temporary, and CVS also warned that costs and macro conditions remain potential headwinds.

Investors watching CVS next will likely focus on whether management can keep its margin recovery on track in subsequent quarters and whether further Aetna operational improvements translate into steady earnings quality. CVS’s own disclosures point to Medicare Advantage policy clarity and prior authorization performance as key near-term operational metrics, and its technology push through Health100 may also become a larger talking point as it moves from concept to measurable adoption.